FiReStarters Part 1
Hosted by David Willis, Senior Foreign Correspondent, BBC: Cynvenio Biosystems: André de Fusco, CEO and Director; Finsphere: Mike Buhrmann, Chairman and CEO; Magnet Systems: Alfred Chuang, Founder and CEO; Spigit Inc.: Paul Pluschkell, Co-Founder and CEO; Wave Systems Corp.: Steven Sprague, CEO
Steven Sprague, Wave Systems – hardware security designed to provide support for integrity and health of program as well as id. Believe in a device-centric model for the future of the world. Solid standards for hardware in the box. Currently no adequate credential store in the smartphone space. “If we could ultimately prove the most success it would be to eliminate your need for passwords.” Eg. Like a garage door opener.
Paul Pluschkell, Spigit — Take crowds and turn them into engaged communities that deliver results. 300,000 NY employees are on Spigit, and problem solved to stop citizens using bottled water, excess paper, etc. Ideas within Spigit move up and are given an IPO. People are coming to work with far more capabilities by using tech to their advantage.
Alfred Chuang, Magnet Systems — Most data youre using is in many different forms, so structuring those, replicating them is very important. @nd wave: Everything is on the cloud.Reinventing not only the way the thing should be built. Former company– BEA systems was sold in 1998 — replaced mainframe server altogether.
Mike Buhrmann, Finsphere — Based on the notion that you can use the cellphone for ID. Where ever, you are, your phone is. And vice versa. Eg. If your credit card is being used in New York and your cellphone is in LA. Work with banks and other enterprise operations and wireless carriers. Networks check in with phone every 5 seconds or less. Awareness of how your info is being used is something to be very aware of.
Andre de Fusco, Cynvenio Biosystems– Focused on cancer diagnostics. Look for circulating cells in the blood of patients. Designed to give doctors a look into the patients. V. focused on breast cancer, preventive diagnostics. Originated in academia, but it’s general and needs to be applied specifically. Very well-suited for finding very rare cells. Privately funded through friends, family and angel investors. Tested 500 patients last year and have a lab at UCLA.